Cargando…
Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials
SUMMARY: The number of people in the United States living with Alzheimer disease (AD) is growing, resulting in significant clinical and economic impact. Substantial research investment has led to drug development in stages of AD before symptomatic dementia, such as preclinical AD. Although there are...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391091/ https://www.ncbi.nlm.nih.gov/pubmed/32584672 http://dx.doi.org/10.18553/jmcp.2020.26.7.888 |